Response of a solid tumor to radiation treatment depends, in part, on the intrinsic radiosensitivity of tumor cells, the proliferation rate of tumor cells between radiation treatments and the hypoxic state of the tumor cells. A successful radiosensitizing agent would target S-phase cells and hypoxia. Recently, we demonstrated the anti-tumor effects of flavopiridol in the GL261 murine glioma model might involve (1) recruitment of tumor cells to S-phase (Newcomb et al., Cell Cycle 2004; 3:230-4) and (2) an anti-angiogenic effect on the tumor vasculature by downregulation of hypoxia-inducible factor-1α (HIF-1α) (Newcomb et al., Neuro-Oncology 2005; 7:225-35). Given that flavopiridol has demonstrated radiosensitizing activity in several murine tumor models, we tested whether it would enhance the response of GL261 tumors to radiation. In the present study, we evaluated the intrinsic radiation sensitivity of the GL261 glioma model using the tumor control/cure dose of radiation assay (TCD 50 ). We found that a single dose of 65 Gy (CI 57.1-73.1) was required to cure 50% of the tumors locally. Using the tumor growth delay assay, fractionated radiation (5 fractions of 5 Gy over 10 days) combined with flavopiridol (5 mg/kg) given three times weekly for three cycles produced a significant growth delay. Our results indicate that the GL261 murine glioma model mimics the radioresistance encountered in human gliomas, and thus should prove useful in identifying promising new investigational radiosensitizers for use in the treatment of glioma patients.
INTRODUCTION
High-grade gliomas are the most common primary CNS tumor in adults and are uniformly fatal despite aggressive therapy. Median survival is approximately 8-12 months. Among the many approaches attempted to improve outcomes, [1] [2] [3] [4] [5] only the combination of temozolomide and radiotherapy have shown a significant improvement. Consequently, the current standard of care for newly diagnosed gliomas remains surgery for resectable tumors followed by external beam radiation therapy with concomitant temozolomide treatment. 6, 7 The dire need for new and more effective chemotherapeutic agents for the treatment of glioma, prompted us to develop the GL261 murine glioma model. 8, 9 Preclinical in vitro and in vivo results supported further investigations using the GL261 cells with the novel cyclin dependent kinase inhibitor flavopiridol. 10, 11 Flavopiridol, a semi-synthetic flavone, has pleiotropic effects as an anti-cancer agent, mechanisms that may be associated with its known ability to affect gene transcription. [12] [13] [14] [15] Our work demonstrated that, as a monotherapy, flavopiridol was effective in delaying GL261 tumors growing in the flank as well as in the brain 11 and this was correlated with an anti-angiogenic effect on the tumor vasculature. 16 Flavopiridol has been investigated for its potential to enhance the effect of radiotherapy in several animal models including human colon, gastric, and lung xenografts and murine ovarian, breast and lymphoma syngeneic tumors. [17] [18] [19] In addition, the GL261 glioma tumor model has been used in several recent studies to screen potential radiosensitizers such as the mTOR inhibitors rapamycin and RAD001, the broad spectrum receptor tyrosine www.landesbioscience.com
Cell Cyclekinase inhibitors SU11248 and SU6668, and the antagonist IC486068 of phosphatidylinositol-3'-kinase using different regimens of fractionated radiotherapy. [20] [21] [22] [23] However, to our knowledge, no studies to date have tested the potential of flavopiridol to enhance the radioresponse of GL261 tumors using the hind limb model. In the present study, we evaluated the intrinsic radiation sensitivity of the GL261 glioma model using the tumor control/cure dose of radiation assay (TCD 50 ). Once we had determined the TCD 50 value, we assessed the effect of different schedules of flavopiridol treatment on radioresponse of the GL261 hind limb tumors to a single dose of irradiation. Using the tumor growth delay assay, we next investigated the radioresponse of GL261 tumors to fractionated radiation combined with flavopiridol. Combination treatment dramatically enhanced the radioresponse of the GL261 tumors resulting in prolonged survivals. Determining the intrinsic radiation sensitivity of the GL261 hind limb tumors establishes the radiation dose required to cure 50% of the tumors locally, providing the baseline data for comparison of combination of radiation with other promising new investigational radiosensitizers for use in the treatment of glioma patients.
MATERIALS AND METHODS
Tumor cell line and reagents. The murine GL261 glioma cell line was cultured in 5% CO 2 and 95% humidified air atmosphere at 37˚C in Dulbecco's Modified Eagles Medium (DMEM) (Gibco BRL, Grand Island, NY) supplemented with 10% fetal bovine serum (Atlanta Biologicals, Norcross, GA), 0.25% Gentamicin (Gibco BRL) and 1% L-glutamine (Gibco BRL). Cells were split every three days to ensure logarithmic growth. Flavopiridol (Aventis Pharmaceuticals, Inc., Bridgewater, NJ) was dissolved in water and stock solution (4 mg/mL) was stored at -20˚C.
Animals and tumor growth. Female C57BL/6 mice were obtained from Charles River Laboratories Inc. (Wilmington, MA) and maintained under aseptic conditions in microisolator cages in facilities approved by the American Association for Accreditation of Laboratory Animal Care, in accordance with the current regulations and standards of the United States Department of Agriculture, The Department of Health and Human Services, and the NIH. Animal studies were performed under an approved protocol by the Institutional Animal Care and Use Committee. The animals were allowed food and water ad libitum. GL261 cells were cultured to sub-confluence, trypsinized, washed twice in DMEM without serum, and resuspended in DMEM before inoculation.
To establish tumors in the hind limb, animals were anesthetized with an intraperitoneal (i.p.) injection of xylazine (80 mg/kg) and ketamine (10 mg/ kg), then injected subcutaneously (s.c.) with 1.5 x 10 6 cells in 0.05 mL of serum-free media into the left hind limb of six to eight week old female C57BL/6 mice. Tumor growth was measured twice weekly using calipers, and tumor volume was calculated using the formula (length x width 2 )/2, where the length represents the longest axis and the width was measured at right angles to the length.
Tumor control/cure dose of radiation (TCD 50 ) assay. Animals bearing established tumors were randomly assigned to control and treatment groups when tumors reached a predetermined size of 7-8 mm-diameter (average of length and width measurements), corresponding to a volume of roughly 300 mm 3 . Each group consisted of five animals. Animals were anesthetized and given a single dose of radiation (20, 30, 40, 50, 60, 70, 80, 90 Gy) to the tumor. Response to treatment was measured by evaluating tumor growth twice weekly using caliper measurement for up to 120 days. Animals were sacrificed when the tumor volume reached 900-1200 mm 3 . Data from two experiments was compiled to determine the dose of radiation required to control 50% of the tumors. The 95% confidence intervals (CI) were calculated by logistic regression analysis. 24, 25 In the second experiment, the scheduledependent effect of flavopiridol treatment was tested on the radioresponse of tumors given a single dose of irradiation. Animals received either vehicle (PBS) alone; flavopiridol alone given daily i.p. (5 mg/kg) for two weeks; single dose radiation of 40 or 50 Gy; and single dose radiation of 40 or 50 Gy combined with one of two different schedules of flavopiridol administration similar to those described previously for the murine ovarian, breast and lymphoma animal models. 19 Tumors were allowed to reach a predetermined size of 7-8 mm-diameter, locally irradiated with 40 or 50 Gy and flavopiridol was given three hours following radiation treatment and then continued daily for two weeks. Alternatively, tumors were allowed to reach a predetermined Table 1 summarizes results from all treatment groups.
size of 6-6.5 mm-diameter and given flavopiridol daily for one week, locally irradiated with 40 or 50 Gy on day +5 and then given flavopiridol treatment daily for a second week. Response to treatment was measured by evaluating tumor growth twice weekly using caliper measurement for up to 120 days. Animals were sacrificed when the tumor volume reached 900-1200 mm 3 .
Tumor growth delay assay. Animals bearing established tumors of approximately 7-8 mm-diameter were randomly assigned to control or treatment groups (N of 5). Tumor-bearing animals were anesthetized and treated. Animals received either vehicle (PBS) alone, flavopiridol alone, radiation without or combined with flavopiridol. A total dose of 25 Gy was administered in five fractions of 5 Gy on days 1, 3, 5, 8 and 10. In the group receiving combination treatment, flavopiridol (5 mg/kg) was administered by i.p. injection following radiation on days 1, 3, 5, 8 and 10 and then four more times on days 12, 15, 17 and 19. This dose and schedule of flavopiridol for three weeks delayed growth of GL261 flank tumors, as we described previously. 11 The tumors were measured twice weekly and the mean tumor volume calculated as described above. Animals were sacrificed when the tumor volume reached > 2500 mm 3 .
Radiation treatment. Animals were anesthetized and positioned on a dedicated plexiglass tray. Irradiation was with a 60 Co source (Theratron 780-C, AECL Medical, Canada) at a dose rate of 134.3 cGy/min and a source-skin distance (SSD) of 80 cm was used. Tumors on the hind limb were treated with a 5 x 5-cm field with remainder of the body shielded with a lead block.
Statistics. For the analysis of radioresponse in the TCD 50 experiments, a logistic model was fitted to the percentage of tumors cured in response to the different radiation doses using the logit method. 24, 25 For analysis of tumor growth delay, we calculated the mean tumor volumes and their standard errors for each of the treatment arms, and used analysis of variance or a mixed-effect model to determine statistical differences. 19 Statistical significance was indicated by values of p < 0.05.
RESULTS
Radioresponse of GL261 tumors to single dose irradiation. First, we tested the GL261 hind limb tumor model in the tumor control/cure dose of radiation assay (TCD 50 ) that measures the dose of radiation necessary to control 50% of the tumors locally. Animals were inoculated with GL261 tumor cells and randomized to control and treatment groups when tumor volumes reached the size of 7-8 mm-diameter. Tumors growing in the hind limb were irradiated with a single dose (20 up to 90 Gy) locally and tumor volumes were measured twice weekly. Tumor regression and time to local recurrence was followed for up to 120 days from the time animals received the single dose of radiation treatment. Figure 1 shows curves of individual mice irradiated with a single dose of 20, 40, 60 or 80 Gy (N of 5/group) for tumor regression and time to local recurrence. Figure 2 shows the radiation-dose-response curve for all the treatment groups (20 up to 90 Gy) used for calculating the TCD 50 value and the 95% confidence interval (CI). Table 1 describes the time in days for local recurrence and the percentage of animals cured by radiation treatment during the 120 day observation period in each experimental group.
The tumor growth curves show the effects of the different radiation treatments on tumor regression and length of time before local recurrence. Tumors irradiated with 20 Gy showed a slight or no decrease in tumor volumes by day 7. In contrast, tumors treated with 40 Gy achieved a dramatic response by day 14, with two animals remaining tumor-free for > 40 and > 60 days. Tumors irradiated with 60 and 80 Gy showed similar tumor regression curves, with tumors regressing within 14 days of treatment and increased numbers of animals remaining tumor-free during the 120 day observation period. The TCD 50 value in mice treated with single dose irradiation was calculated as 65.0 Gy (95% confidence interval = 57.1-73.1) (Fig. 2 ). These results demonstrate that the murine GL261 hind limb tumors are relatively radioresistant, with even the highest dose of 90 Gy unable to produce a 100% cure rate ( Table 1) .
Effect of flavopiridol on radioresponse of GL261 tumors to single dose irradiation. Based on the results of the TCD 50 assay, we selected two doses of irradiation below the 65 Gy TCD 50 value, 40 and 50 Gy, in order to test the effect of flavopiridol on radioresponse. We tested two schedules of administration of flavopiridol, either given before or after radiation treatment. If one of the treatment schedules is more effective, than we would expect a higher tumor cure rate or longer intervals between tumor regression and time for measurable tumors to reappear. Figure 3 shows curves of individual mice for tumor regression and time to local recurrence. Table 2 summarizes the time in days for local recurrence and percentage of animals cured during the 120 day observation period in all of the experimental groups. Flavopiridol treatment enhanced the radioresponse of tumors to single dose 40 and 50 Gy irradiation. The combination of flavopiridol plus radiation resulted in longer tumor free intervals compared with radiation treatment alone, indicating that flavopiridol potentiated the response of the GL261 tumors to radiation. Whether flavopiridol was given both before and after radiation or given only after radiation, the tumor free intervals were comparable for the 40 Gy treatment groups. However, in the 50 Gy treatment groups, radiation followed by flavopiridol showed an average of 83 days tumor free interval compared with an average of 66 days for animals treated with flavopiridol given both before and after radiation treatment. This trend for enhanced radioresponse using this treatment schedule of radiation followed by flavopiridol has been reported previously. 18, 19 Effect of flavopiridol on radioresponse of GL261 tumors to fractionated radiotherapy. To determine whether flavopiridol Flavopiridol Enhances Radioresponse of GL261 Glioma Figure 2 . The radiation-dose-response curve of the GL261 glioma model derived from the TCD 50 assay. Animals bearing 7-8 mm-diameter hind limb tumors were given local irradiation with graded doses of radiation (20 up to 90 Gy) delivered as a single dose. The radiation-dose-response curve was generated for local tumor control/cure at 120 days after treatment. Error bars are 95% confidence intervals on the TCD 50 .
enhances the response of GL261 tumors to fractionated radiotherapy, which is more clinically relevant, we tested a regimen of fractionated radiation followed by flavopiridol treatment in the tumor growth delay assay. Animals with established hind limb tumors were randomly assigned to four treatment groups when tumors reached 7-8 mm-diameter in size: (1) control given PBS three times weekly for three weeks; (2) flavopiridol only at a dose of 5 mg/kg three times weekly for three weeks; (3) radiation only, five fractions of 5 Gy for a total dose of 25 Gy, or 4) a combination of radiation followed by flavopiridol. Figure 4 shows the effect of the different treatments on the growth of the GL261 tumors over a seven week interval. At three weeks, prior to the sacrifice of animals in the radiation or radiation plus flavopiridol treatment groups, the mean tumor volumes were compared to those of the flavopiridol treatment group to determine extent of tumor growth delay. Flavopiridol treatment alone induced a growth delay of about one week compared with controls, with tumors showing a mean volume of 2444 ± 389 mm 3 . Radiation treatment alone produced a more pronounced growth delay compared with flavopiridol treatment alone with animals having tumors of 1084 ± 250 mm 3 mean volume. The combination of radiation plus flavopiridol produced the most significant reduction in tumor volumes. The mean volume of the tumors treated with radiation plus flavopiridol was 564 ± 60 mm 3 , a 50% decrease in mean tumor volume compared with the radiation treatment group and > 75% decrease in mean tumor volume compared with the flavopiridol treatment group. Using analysis of variance for the tumor volumes data after day 7, the pair-wise difference among growth curves were all statistically significant (p < 0.05). Using mixed-effect model analysis, statistically significant differences between the tumor growth of any of the treatment groups compared to that of the control group were detected (p < 0.05).
DISCUSSION
In this study we characterized the intrinsic radiation sensitivity of the GL261 murine glioma model using the tumor control/cure TCD 50 assay. This assay establishes the radiation dose required to cure 50% of the tumors locally. A total dose of 65.0 Gy was calculated to achieve cures in 50% of the animals bearing established GL261 hind limb tumors. For comparison, we examined the literature for TCD 50 values of fifteen tumor models consisting of twelve different murine carcinomas used in syngeneic C3H/Kam mice and three different human glioma xenografts used in immuno-compromised nude mice. The TCD 50 value of the GL261 tumor model, compared with the TCD 50 values of the other tumor models, are summarized in Table 3 . [26] [27] [28] [29] [30] [31] The TCD 50 values ranged from relatively radiosensitive (six of 16 tumor models had values between 42.9-58.3 Gy) to highly radioresistant (4 of 16 tumor models had values between 75.2-83.1 Gy). The radiosensitivity of the GL261 glioma tumor model was intermediate (5 of 16 tumor models had values between 62.3-67.6 Gy). However, both the human glioma U87MG xenograft model and the murine glioma GL261 syngeneic tumor model showed a high level of radioresistance mimicking the characteristic clinical radioresistance associated with high-grade human gliomas.
Flavopiridol treatment enhanced the anti-tumor effect of both single and fractionated doses of irradiation in the GL261 tumor model. It is well known that the sequence of administration of drugs or combination of treatment therapies is important in determining the most effective course of treatment. 32 Our results demonstrate that the combination of flavopiridol with radiation is more effective than either treatment separately, with slightly better efficacy demonstrated when flavopiridol was given after radiation treatment. Previous studies have shown that flavopiridol has radiosensitizing effects in several other animal model systems including human colon, gastric and lung xenografts and murine ovarian, breast and lymphoma Tumors were allowed to reach a predetermined size of 7-8 mm-diameter, locally irradiated with 40 Gy (40 Gy + F) or 50 Gy (50 Gy + F) and flavopiridol was given three hours following radiation treatment and then continued daily for two weeks. Alternatively, tumors were allowed to reach a predetermined size of 6-6.5 mm-diameter and given flavopiridol daily for one week, locally irradiated with 40 Gy (F + 40 Gy + F) or 50 Gy (F + 50 Gy + F) on day + 5 and then given flavopiridol treatment daily for a second week. Each line within a given treatment group represents an individual animal and records the changes in tumor volumes measured twice weekly for up to 120 days. Animals were sacrificed when tumor volumes reached ~1000 mm 3 . Table 2 summarizes the results from all treatment groups. syngeneic tumors and anti-tumor activity was potentiated when flavopiridol was administered following radiation. [17] [18] [19] Response of a solid tumor to radiation treatment depends, in part, on the intrinsic radiosensitivity of tumor cells, the proliferation rate of tumor cells between radiation treatments and the hypoxic state of the tumor cells. We and others have shown that flavopiridol is an S-phase specific drug. 11, [33] [34] [35] We elected to give fractionated radiation in a protracted schedule of 5 fractions of 5 Gy delivered over ten days in order to test our hypothesis that flavopiridol would selectively kill proliferating cells in S phase, by overcoming repopulation of tumor cells between fractionated radiation treatments. 36, 37 In addition to its ability to kill cells in S phase, flavopiridol also can recruit cells into the S phase when it is delivered 48 or 72 h apart. 11, 32 Our results demonstrate that the schedules chosen for radiation and flavopiridol treatments produced a highly significant delay in tumor growth. Since noncycling cells are relatively radio-resistant, the enhanced radiosensitizing effects of flavopiridol observed in this study of repeated doses of both radiation and flavopiridol treatments can be hypothesized to be due, at least in part, to its ability to affect tumor repopulation. 38 Future studies will be needed to elucidate the ongoing balance between apoptosis and proliferation in the GL261 glioma tumor model.
An important factor involved in the radioresponse of a tumor is the hypoxic microenvironment. Overexpression of hypoxia-inducible factor-1 (HIF-1), a common feature in solid malignancies, is related to oxygen deficiencies occurring via multiple mechanisms including, increased proliferation of tumor cells, lack of oxygen diffusion, decreased blood flow, and abnormal tumor vasculature. As a result, HIF-1 and its signaling pathway have become targets for cancer chemotherapy. [39] [40] [41] [42] A benefit of agents that affect HIF-1 activity or HIF-1α expression would be the prevention of activation of HIF-1 target genes, such as vascular endothelial growth factor (VEGF), which can contribute to tumor angiogenesis and promote tumor growth potential. Both the tumor cells and the endothelial cells of the tumor vasculature secrete and respond, respectively, to the potent angiogenic factor, VEGF. Radiation is known to increase secretion of VEGF by tumor cells and this has been associated with increased resistance to radiation treatments, in part, associated with its ability to protect tumor blood vessels from radiation induced cell death. [43] [44] [45] Thus, agents that can block radiation-induced VEGF secretion or its binding to its receptor, VEGFR, are two strategies that have been used to increase anti-tumor effects of radiation. [21] [22] [23] [44] [45] [46] [47] [48] Although the mechanisms by which flavopiridol enhanced anti-tumor effects when combined with radiation were not evaluated in this study, based on its known anti-angiogenic activity in a variety of in vivo models, 14, 16, 49, 50 it is likely that one mechanism involved is due to its ability to inhibit angiogenesis. Recently, we demonstrated that flavopiridol inhibited the HIF-1 pathway by downregulation of HIF-1α expression, concomitant with decreased VEGF secretion by glioma cells. 16 When we analyzed vascular density in intracranial GL261 tumors from control and flavopiridol treated animals, the tumors from drug-treated animals had significantly fewer blood vessels compared with tumors from control animals, suggesting that flavopiridol inhibited angiogenic activity. 16 This conclusion is further supported by two other recent in vivo studies. Using zebrafish as an in vivo model to screen anti-angiogenic compounds for their effects on activated vascular endothelial cells, several known small molecule inhibitors of angiogenesis, were used to validate the potential of the animal model. 49 Flavopiridol, similar to paclitaxel, inhibited proliferation of the vascular endothelial cells in a dose-dependent manner. 49 In another study, modulation of tumor hypoxia was assessed via a reporter protein marker, β-human chorionic gonadotropin (hCG), linked to five tandem repeats of the hypoxia-response element. Tumor cells stably transfected with the construct and implanted into mice showed increased secretion of β-hCG in the urine in response to hypoxia that was decreased following treatment of mice with flavopiridol. 50 Thus, flavopiridol was able to decrease the level of a HIF-reporter gene, most likely due to its well known ability to inhibit mRNA synthesis. [13] [14] [15] [16] 51 In summary, we have shown that the GL261 murine glioma model mimics the radioresistance encountered in human gliomas. Flavopiridol showed anti-tumor effects on GL261 tumors alone, 11 but when combined with radiation it proved to significantly enhance the radioresponse of the GL261 glioma tumors. Although flavopiridol as a monotherapy has had little success in clinical trials to date, the option to use combination therapies, as we have shown here, offers the opportunity to improve the outcome of refractory tumors, such as high-grade gliomas. , and MCa-K); two squamous cell carcinomas (SCC-IV, SCC-VIII); an ovarian adenocarcinoma (Oca-I); a hepatocarcinoma (Hca-I); an adenosquamous carcinoma (Aca-SG); three fibrosarcomas (SA-NH, NFSA, and FSA); and one glioma syngeneic to C57BL/6 mice (GL261). nd=not determined.
